Cargando…

Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant

We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Abhyankar, Mayuresh M., Mann, Barbara J., Sturek, Jeffrey M., Brovero, Savannah, Moreau, G. Brett, Sengar, Anjali, Richardson, Crystal M., Agah, Sayeh, Pomés, Anna, Kasson, Peter M., Tomai, Mark A., Fox, Christopher B., Petri, William A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602664/
https://www.ncbi.nlm.nih.gov/pubmed/34795290
http://dx.doi.org/10.1038/s41541-021-00399-0